Q1 2026 Earnings Call May 1, 2026 11:00 AM EDTCompany ParticipantsNicholas Manthey - Chief Financial OfficerJeff Lorberbaum ...
OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first quarter of 2026 and recent weeks included ...
Q1 2026 Earnings Call April 29, 2026 4:25 PM EDTCompany ParticipantsStan Finkelstein - Head of Investor RelationsMike Slessor - ...
Detailed price information for Generac Holdings Inc (GNRC-N) from The Globe and Mail including charting and trades.
In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a ...
Viking Therapeutics, Inc. (Viking) , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial ...
Parents who gain access to usage logs can see just how much time their children spend inside YouTube's recommendation engine ...
NR3C1 encodes the glucocorticoid receptor (GR) and regulates stress responses, metabolism, immune function, and inflammation, ...
Welcome to our first quarter 2026 conference call to discuss financial and operational results. I will begin by providing a summary of the first quarter results and then turn the call over to Kelly ...
In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist1The trial met both weight l ...
Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% del ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results